Erschienen in:
07.01.2021 | ASO Author Reflections
ASO Author Reflections: Age Is an Important Determinant of Concordance Between 21-Gene Recurrence Scores in Multiple Ipsilateral Breast Carcinomas
verfasst von:
Kate R. Pawloski, MD, Audree B. Tadros, MD, MPH, Mahmoud El-Tamer, MD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
Multifocal and multicentric (MF/MC) breast cancers (BCs) are identified more frequently with increased use of magnetic resonance imaging (MRI) and other advanced imaging methods.
1 MF/MC BC is associated with higher-risk pathologic features
2,3 which have traditionally necessitated chemotherapy. However, multigene assay testing such as the Oncotype DX Recurrence Score (RS) for estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2−) axillary node-negative BC treated with endocrine therapy has permitted more personalized identification of women who will benefit from chemotherapy.
4 Concordance in RS between MF/MC lesions, defined as no change in management based on RS difference, is high for women with morphologically similar lesions.
5 Based on the TAILORx trial, women 50 years old or younger with intermediate RS (16–25) derive a larger benefit from adjuvant chemotherapy than their older counterparts with similar scores. The number of foci that should be tested to minimize the risk of undertreatment remains unclear, particularly for young women, for whom a lower threshold is used to determine the need for chemotherapy than those older than 50 years. …
